tetano
Editor, Senior Moderator
J Med Virol
. 2022 Mar 24.
doi: 10.1002/jmv.27738. Online ahead of print.
Reverse genetics systems for SARS-CoV-2
Wenhao Wang[SUP] 1 [/SUP], Xiaoxue Peng[SUP] 1 [/SUP], Yunyun Jin[SUP] 1 [/SUP], Ji-An Pan[SUP] 1 [/SUP], Deyin Guo[SUP] 1 [/SUP]
Affiliations
Abstract
The ongoing pandemic of coronavirus disease 2019 (COVID-19) has caused severe public health crises and heavy economic losses. Limited knowledge about this deadly virus impairs our capacity to set up a toolkit against it. Thus, more studies on SARS-CoV-2 biology are urgently needed. Reverse genetics systems, including viral infectious clones and replicons, are the powerful platforms for the viral research projects, spanning many aspects such as the rescues of WT or mutant viral particles, the investigation of viral replication mechanism, the characterization of viral protein functions, and the studies on viral pathogenesis and antiviral drug development. The operations on viral infectious clones are strictly limited in the Biosafety Level 3 (BSL3) facilities, which are insufficient, especially during the pandemic. In contrast, the operation on the non-infectious replicon can be performed in Biosafety Level 2 (BSL2) facilities, which are widely available. After the outbreak of COVID-19, many reverse genetics systems for SARS-CoV-2, including infectious clones and replicons are developed and gave plenty of options for researchers to pick up according to the requirement of their researches. In this review, we summarize the available reverse genetics systems for SARS-CoV-2, by highlighting the features of these systems, and provide a quick guide for researchers, especially those without ample experience in operating viral reverse genetics systems. This article is protected by copyright. All rights reserved.
Keywords: BAC; CPER; Reverse genetics systems; SARS-CoV-2; TAR.
. 2022 Mar 24.
doi: 10.1002/jmv.27738. Online ahead of print.
Reverse genetics systems for SARS-CoV-2
Wenhao Wang[SUP] 1 [/SUP], Xiaoxue Peng[SUP] 1 [/SUP], Yunyun Jin[SUP] 1 [/SUP], Ji-An Pan[SUP] 1 [/SUP], Deyin Guo[SUP] 1 [/SUP]
Affiliations
- PMID: 35324008
- DOI: 10.1002/jmv.27738
Abstract
The ongoing pandemic of coronavirus disease 2019 (COVID-19) has caused severe public health crises and heavy economic losses. Limited knowledge about this deadly virus impairs our capacity to set up a toolkit against it. Thus, more studies on SARS-CoV-2 biology are urgently needed. Reverse genetics systems, including viral infectious clones and replicons, are the powerful platforms for the viral research projects, spanning many aspects such as the rescues of WT or mutant viral particles, the investigation of viral replication mechanism, the characterization of viral protein functions, and the studies on viral pathogenesis and antiviral drug development. The operations on viral infectious clones are strictly limited in the Biosafety Level 3 (BSL3) facilities, which are insufficient, especially during the pandemic. In contrast, the operation on the non-infectious replicon can be performed in Biosafety Level 2 (BSL2) facilities, which are widely available. After the outbreak of COVID-19, many reverse genetics systems for SARS-CoV-2, including infectious clones and replicons are developed and gave plenty of options for researchers to pick up according to the requirement of their researches. In this review, we summarize the available reverse genetics systems for SARS-CoV-2, by highlighting the features of these systems, and provide a quick guide for researchers, especially those without ample experience in operating viral reverse genetics systems. This article is protected by copyright. All rights reserved.
Keywords: BAC; CPER; Reverse genetics systems; SARS-CoV-2; TAR.